| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 1,030 | 670 | 680 | 940 | 570 |
| Sales Growth | +53.73% | -1.47% | -27.66% | +64.91% | -6.56% |
| Net Income | -40,590 | -42,460 | -33,750 | -39,970 | -27,270 |
| Net Income Growth | +4.40% | -25.81% | +15.56% | -46.57% | -28.39% |
Upstream Bio Inc (UPB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Upstream Bio Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in development which targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio Inc. is based in WALTHAM, Mass.
Fiscal Year End Date: 12/31